Managing malignant disease in patients with porphyria

QJM: An International Journal of Medicine

Volumn 97, Issue 3, 2004, Pages 115-126

  Palmieri, C ^a   Vigushin, D M ^a   Peters, T J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; ANXIOLYTIC AGENT; ASPARAGINASE; AZATHIOPRINE; BENZODIAZEPINE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; LIDOCAINE; MELPHALAN; MESUXIMIDE; METHOTREXATE; METHYLAMINE; MITOMYCIN C; MITOXANTRONE; PHENOTHIAZINE; PORPHYRINOGEN; PROCARBAZINE; SEDATIVE AGENT; TIOGUANINE; UNINDEXED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURGERY; CARBOHYDRATE DIET; CARCINOGENESIS; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; FOLLICULAR LYMPHOMA; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; NONHUMAN; PORPHYRIA; PREMEDICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SOLID TUMOR;

EID: 1542604148     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hch027     Document Type: Review

References (70)

1. Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. Br Med J 2000; 320:1647-51.
2. Kaczynski J, Hansson G, Thunell S, Watterberg L, Wallerstedt S. Erythrocyte porphobilinogen deaminase activity and primary liver cancer. J Int Med 1995; 237:309-313.
3. Tio TH, Leijnse B, Jarrett A, Rimington C. Acquired porphyria from a liver tumour. Clin Sci 1957; 16:517-27.
4. Gross U, Schurek JO, Doss M, Doss MO. Haem arginate interferes with estimation of carcinoembryonic antigen. Ann Clin Biochem 2001; 38:275-6.
5. McNeill MJ, Bennet A. Use of regional anaesthesia in a patient with acute porphyria. Br J Anaesth 1990; 64:371-3.
6. Joyau M, Deybach JC, Durand M, Parmentier G, Nordmann Y. Peridural anaesthesia with procaine and fentanyl in a parturient with acute intermittent prophyria. Ann Franc Anesthes Reanimat 1986; 5:453-5.
7. Brennan L, Halfacre JA, Woods SD. Regional anaesthesia in porphyria. Br J Anaesth 1990; 65:594.
8. Bohrer H, Schmidt H. Regional anesthesia as anesthetic technique of choice in acute hepatic porphyria. J Clin Anesth 1992; 4:259.
9. Jensen NF, Fiddler DS, Striepe V. Anaesthetic considerations in porphyrias. Anesth Analg 1995; 80:591-9.
10. Evans PR, Graham S, Kumar CM. The use of sevoflurane in acute intermittent porphyria. Anaesthesia 2001; 56:388-9.
11. James MF, Hift RJ. Porphyrias. Br J Anaesth 2000; 85:143-53.
12. Schaffer M, Schaffer P, Panzer M, Wilkowski R, Duhmke E. Porphyrias associated with malignant tumours: Results of treatment with ionizing irradiation. Onkologie 2001; 24: 170-2.
13. Maughan WZ, Muller SA, Perry HO. Porphyria cutanea tarda associated with lymphoma. Acta Dermato Venereol 1979; 59:55-8.
14. Scarlett JD, Corry J, Jeal PN. Cytotoxic chemotherapy and a radiotherapy in a patient with breast cancer and variegate porphyria. Aust NZ J Med 1995; 25:742-3.
15. Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall-another call with tamoxifen. Acta Oncol 1999; 38: 955-9.
16. Agarwal R, Peters TJ, Coombes RC, Vigushin DM. Tamoxifen-related porphyria cutanea tarda. Med Oncol 2002; 19:121-3.
17. De Matteis F. Disturbances of liver porphyrin metabolism caused by drugs. Pharmacol Rev 1967; 19:523-57.
18. Racz WJ, Marks GS. Drug-induced porphyrin biosynthesis. II. Simple procedure for screening drugs for porphyria-inducing activity. Biochem Pharmacol 1969; 18:2009-18.
19. Cochon AC, Aldonatti C, San Martin de Viale LC, De Calmanovici RW. Evaluation of the porphyrinogenic risk of antineoplastics. J Appl Toxicol 1997; 17:171-7.
20. Palma-Carlos AG, Palma-Carlos ML, Lourenco MG, Martins-Silva JA. Effect of alkylating agents on haem metabolism. S Af J Lab Clin Med 1971; 25:81-4.
21. Rizzardini M, Ferraroli A, Dal Fiume D, Cantoni L. Cyclophosphamide impaired regulation of hepatic heme metabolism. Experientia 1984; 40:1390-2.
22. Kyle R, Dameshek W. Porphyria cutanea tarda associated with chronic granulocytic leukemia treated with busulfan. Blood 1961; 23:776-85.
23. Gonzalez A, Roman P, Garcia FJ, Gonzalez Q. Case of porphyria after treatment with cisplatin. Med Clin 1986; 97:738-9.
24. Manzione NC, Wolkoff AW, Sassa S. Development of porpohyria cutanea tarda after treatment with cyclophosphamide. Gastroenterology 1988; 95:1119-22.
25. Malina L, Chlumsky J, Chlumska A, Krtek V. Porphyria cutanea tarda (PCT) als folge der methotrexat-und buthiopurin-therapie. Z Hautkr 1983; 58:645-63.
26. O'Neill T, Simpson J, Smyth SJ, Lovell C, Calin A. Porphyria cutanea tarda associated with methotrexate therapy. Br J Rheum 1993; 32:411-12.
27. Samuels B, Bezwoda WR, Derman DP, Goss G. Chemotherapy in porphyria. S Afr Med J 1984; 65:924-6.
28. Scarlett JD, Corry J, Jeal PN. Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP). Aust N Z J Med 1995; 25:742-3.
29. Wehmeier A, Fitcher J, Goerz G, Schneider W. Poly-chemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria. Klin Wochenschr 1987; 65:338-40.
30. Rayhanzadeh S, Shoss RG, Noyes J. Porphyria cutanea tarda associated with lymphosarcoma. Arch Dermatol 1975; 111:129.
31. Arbus M. Relationship between porphyria and the use of antineoplastics. Am J Hosp Pharm 1981; 38:631.
32. Yull G. Actinomycin-D treatment in a case of acute intermittent porphyria. Lancet 1970; 2:216-17.
33. Forget F, Awada A, Klastersky J. Anticancer chemotherapy in a patient with a prior history of acute intermittent porphyria. Support Care Cancer 2001; 9:465-6.
34. Meyer U, Schuurmans M, Lindberg R. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998; 18:43-52.
35. Rayhanzadeh S, Shoss RG, Noyes J. Porphyria cutanea tarda associated with lymphosarcoma. Arch Dermatol 1975; 111:129.
36. Dopfer R, Doss M, Ehninger G, Ostendorf P, Niethammer D. Appearance of an inherited porphyria cutanea tarda in a child after allogenic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1986; 1:95-9.
37. Ho AY, Deacon A, Osborne G, Mufti GJ. Precipitation of porphyria cutanea tarda by Imatinib Mesylate? Br J Haem 2003; 121:375.
38. Malina L, Michalikova H, Hussarova L. Porphyria cutanea tarda after antineoplastic drugs. Casopis Lekaru Ceskych 1999; 138:536-8.
39. Claus A, Gail P. Tamoxifen and porphyria. In: Millenium meeting on porphyrins and porphyrias 2000. Paris, Institut Pasteur, 2000.
40. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumont Inoma T, Enzan H, Onishi S, Yoshida S. Unrecognized heaptic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Obcol Rep 2000; 7:1299-304.
41. Aramideh M, Koopsmans RP, Koelman JHTM, Stam J. Rapidly progressing peripheral neuropathy with lactic acidosis and coproporphyria in a patient with with HTLV-I associated T-cell leukaemia treated with zidovudine. J Neurol 2001; 248:621-2.
42. Herrero C, Bassas S, Azon A, Masxaro JM, Miro J. Acquired immunodeficiency syndrome in a patient affected by hereditary coproprohyria: Safety of zidovudine treatment. Arch Dermatol 1990; 126:122-3.
43. Nolte FS, Arnold KE, Sweat H, Winston EF, Funke G. Vancomycin-resistant Aureobacterium species cellulitis and bacteremia in a pateint with acute myelogenous leukemia. J Clin Microbiol 1996; 34:1992-4.
44. Oubre D, Cruz J, Keung Y. Porphyria cutanea tarda in a patient with post transplant MDS. Bone Marrow Transplantation 2001; 27:219-20.
45. De Wet J, Coccia-Portugal MA, Falkson G. Ondansetron in a patient with porphyria. SAMJ 1992; 82:480.
46. Disler PB, Moore MR. Drug therapy in the acute porphyria. Clin Dermatol 1985; 3:112-24.
47. Ramsey CA, Magnus IA, Turnbull A, Baker H. The treatment of porphyria cutanea tarda by venesection. Q J Med 1974; 43:1-24.
48. Reynolds NC, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology 1981; 31:480-4.
49. Yandel ML, Watters MR. Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resceted anaplastic glioma. Clinical Neurol Neurosurg 1995; 97:261-3.
50. Peters H. Acute hepatic porphyria. In: Johnston R, ed. Current therapy in neurologic disease. BC Decker, 1985.
51. Labiner DM, Ahern GL, Kolb MA, Johnston DS, Vengrow MI. Gabapetin is both safe and effective in treating seizures associated with porphyria. Epilepsia 1994; 35(Suppl.):53.
52. Winkler AS, Marsden J, Deacon A, Wilson S, Chandler G, Macdougall IC, Peters TJ. Serum erythropoietin levels may be inappropriately low in the acute neuropsychiatric porphyrias. Clin Chim Acta 2002; 317:93-100.
53. Laidman PJ, Gabauer K, Trotter J. 5-flouorouracil-induced pseudoporphyria. Aust NZ J Med 1992; 22:385. '
54. Falkson G, Schultz FJ. Skin changes in a patient with 5-fluorouracil. Br J Dermatol 1962; 74:229-36.
55. Borroni G, Brazzelli V, Baldini F, Borghini F, Gaviglio MR, Beltrami B, et al. Flutamide-induced pseudoporphyria. Br J Dermatol 1998; 138:711-12.
56. Mantoux F, Bahadoran P, Perrin C, Bermon C, Lacour JP, Ortonne JP. Flutamide induced late cutaneous psuedoporphyria. Ann Dermatol Venerol 1999; 126:150-2.
57. McDonagh AJ, Harrington CI. Pseudoporphyria complicating etreinate therapy. Clin Exp Dermatol 1989; 14:437-8.
58. LaDuca JR, Bouman PH, Gaspari AA. Nonsteroidal anti-inflammatory drug induced pseudoporphyria: A case series. J Cutan Med Surg 2002; 6:320-6.
59. Cummins R, Wagner-Weiner L, Paller A. Psedoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis. J Rheumatol 2000; 12:2938-40.
60. Anderson KE, Goeger DE, Carson RW, Lee SM, Stead RB. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long term hemodialysis. N Engl J Med 1990; 322:315-17.
61. Yaqoob M, Smyth J, Ahmad R, McClelland P, Fahal I, Kumar KAR, Verbov J. Haemodialysis-related porphyria cutanea tarda and treatment by recombinant human erythropoietin. Nephron 1992; 60:428-31.
62. Peces R, Enriquez de Salamanca R, Fontanellas A, Sanchez A, de la Torre M, Capparros G, Ferreras I, Nieto J. Successful treatment of haemodialysis-realted porphyria cutanea tarda with erythropoietin. Nephrol Dial Transplant 1994; 4:433-5.
63. Taylor RL. Magnesium sulfate for AIP seizures. Neurology 1981; 31:1371-2.
64. Morris DL, Dudley MD, Pearson RD. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med 1981; 95:700-1.
65. Ashley EM. Anaesthesia for porphyria. Br J Hosp Med 1996; 56:37-42.
66. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Int Med 1993; 153:2004-8.
67. Horie Y, Tanaka K, Okano J, Kawasaki H, Yamamoto S, Kondo M, Sassa S. Cimetidine in the treatment of porphyria cutanea tarda. Intern Med 1996; 35:717-19.
68. Rogers PD. Cimetidine in the treatment of acute intermittent porphyria. Ann Pharmacother 1997; 31:365-7.
69. Medenica R, Lazovic G, Long P, Corbitt W, Powell D. Plasmapheresis combined with somatostatin is a successful treatment of porphyrias. Ther Apher 1997; 1:159-64.
70. Galbraith RA, Kappas A. Pharmokinetics of tinmesoporphyrin in man and the effects on tin-chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria. Hepatology 1989; 9:882-8.